Shopping Cart
  • Remove All
  • TargetMol
    Your shopping cart is currently empty

c-Myc

Myc is a family of regulator genes and proto-oncogenes that code for transcription factors. The Myc family consists of three related human genes: c-myc (MYC), l-myc (MYCL), and n-myc (MYCN). c-myc (also sometimes referred to as MYC) was the first gene to be discovered in this family, due to homology with the viral gene v-myc.

MYCi975
T121332289691-01-4
MYCi975 (NUCC-0200975) is an orally active MYC inhibitor.
  • $127
In Stock
Size
QTY
TargetMol | Inhibitor Sale
Agrimol B
T4S117355576-66-4
1. Agrimol B is a main active ingredient isolated from Agrimonia pilosa Ledeb.
  • $116
In Stock
Size
QTY
Fucoxanthin
T76003351-86-8
Fucoxanthin (all-trans-Fucoxanthin) is a carotenoid naturally found in certain algae, serving as an accessory pigment in the chloroplasts of brown algae and most other heterokonts, which imparts a brown or olive-green color. It exhibits anti-obesity, antioxidant, anti-diabetic, anticancer, and anti-inflammatory activities.
  • $30
In Stock
Size
QTY
TargetMol | Citations Cited
Idarubicin hydrochloride
T601057852-57-0
Idarubicin hydrochloride (Zavedos), a hydrochloride salt form of Idarubicin, is a DNA topoisomerase II (topo II) inhibitor for MCF-7 cells ( IC50: 3.3 ng mL).
  • $55
In Stock
Size
QTY
TargetMol | Citations Cited
Trachelogenin
TN650834209-69-3
Trachelogenin ((-)-Trachelogenin), isolated from Combretum fruticosum, is an HCV entry inhibitor with anti-proliferative effects. Its mechanism is related to affecting the phosphorylation of key proteins such as β-Catenin, c-Myc and GSK3 in the β-Catenin signaling pathway. chemical and concentration-dependent. Trachelogenin has antiviral, anti-inflammatory and analgesic activities with IC50 of 0.325 and 0.259 μg mL in HCVcc and HCVpp models, respectively.
  • $139
In Stock
Size
QTY
Lusianthridin
TN189287530-30-1
Lusianthridin is a natural product from Dendrobium venustum. Lusianthridin exhibits anti-migratory property at nontoxic concentrations. Lusianthridin enhances c-Myc degradation through the inhibition of Src-STAT3 signaling.
  • $217
In Stock
Size
QTY
NY2267
T9093886053-73-2
NY2267 (Acetic acid, 2-[[6-[2-(cyclohexylamino)-1-[[(4-methoxyphenyl)methyl](2-pyridinylcarbonyl)amino]-2-oxoethyl]-2-naphthalenyl]oxy]-, 1,1-dimethylethyl ester) is a disruptor of Myc-Max interaction, with an IC50 of 36.5 μM.
  • $89
In Stock
Size
QTY
10058-F4
T3048403811-55-2
10058-F4 (c-Myc Inhibitor) is a cell-permeable thiazolidinone that specifically inhibits the c-Myc-Max interaction and prevents transactivation of c-Myc target gene expression; induces cell-cycle arrest and apoptosis.
  • $43
In Stock
Size
QTY
TargetMol | Citations Cited
MYCMI-6
T12134681282-09-7
MYCMI-6 (NSC-354961) is a potent and selective inhibitor of endogenous MYC:MAX protein interactions,reduces proliferation and induces massive apoptosis in tumor tissue from a MYC-driven xenograft tumor model without severe side effects.
  • $68
In Stock
Size
QTY
Momordin Ic
T341096990-18-0
Momordin Ic (Momordin 1c) might represent a potential anticancer activity, by inducing apoptosis through oxidative stress-regulated mitochondrial dysfunction involving the MAPK and PI3K-mediated iNOS and HO-1 pathways. Also, Momordin Ic accelerates gastrointestinal transit partially by stimulating synthesis of 5-HT to act through 5-HT(2), which, in turn, increases synthesis of prostaglandins.
  • $30
In Stock
Size
QTY
TargetMol | Inhibitor Sale
APTO-253
T10352916151-99-0
APTO-253 (LOR-253) inhibits c-Myc expression, stabilizes G-quadruplex DNA, and induces cell cycle arrest and apoptosis in acute myeloid leukemia cells. APTO-253 mediates anticancer activity through the induction of the KLF4 tumor suppressor.
  • $36
In Stock
Size
QTY
Mollugin
T367355481-88-4
Mollugin (Rubimaillin) may be a JAK2 inhibitor and inhibits LPS-induced inflammatory responses by blocking the activation of the JAK-STAT pathway. Mollugin as a candidate for a chemotherapeutic agent in OSCCs via the upregulation of the HO-1 and Nrf2 pathways and the downregulation of NF- κ B. Mollugin may be a novel therapeutic candidate for bone loss-associated disorders including osteoporosis, rheumatoid arthritis, and periodontitis. Also, it has anticancer efficacy, can modulate the HER2 pathway in HER2-overexpressing Y cells with a potential role in the treatment and prevention of human breast and ovarian Y with HER2 overexpression.
  • $39
In Stock
Size
QTY
EN4
T90611197824-15-9
EN4 (EN4 MYC inhibitor) MYC inhibitor is a covalent ligand that targets cysteine 171 (C171) of MYC. It is selective for c-MYC over N-MYC and L-MYC, and inhibits MYC transcriptional activity, downregulates MYC targets, and impairs tumorigenesis.
  • $32
In Stock
Size
QTY
BTYNB
T9033304456-62-0
BTYNB (MDK6620) is an inhibitor of the oncofetal mRNA-binding protein IMP1 (IC50 = 5 μM for IMP1 binding to c-Myc mRNA). MDK6620 downregulates β-TrCP1 mRNA and reduces activation of nuclear transcriptional factors-kappa B (NF-κB). It disrupts this enhancer function by impairing IGF2 mRNA-binding protein 1 (IGF2BP1)-RNA association
  • $40
In Stock
Size
QTY
KL4-219A
T204093
KL4-219A is a selective covalent degrader of the oncogenic transcription factor MYC, inhibiting MYC transcriptional activity and degrading MYC in a proteasome-dependent manner by targeting intrinsically disordered C203 and D205 residues.
  • $143
In Stock
Size
QTY
IRES-C11
T40419342416-30-2
IRES-C11 is a specific inhibitor of translation that targets the internal ribosome entry site (IRES) of the c-MYC gene. It functions by blocking the interaction between heterogeneous nuclear ribonucleoprotein A1, a trans-acting factor required for c-MYC IRES activity, and its corresponding IRES. Notably, IRES-C11 does not inhibit the IRES activity of BAG-1, XIAP, and p53.
  • $105
In Stock
Size
QTY
10074-G5
T3686413611-93-5
10074-G5 is an inhibitor of c-Myc-Max dimerization.
  • $35
In Stock
Size
QTY
VPC-70063
T6001913571-44-3
VPC-70063 (Thiourea, N-[3,5-bis(trifluoromethyl)phenyl]-N'-(phenylmethyl)-) is an inhibitor of c-Myc-MAX. VPC-70063 exhibits Myc-Max transcriptional activity inhibition of 106% with an IC50 of 8.9 μM and Myc-Max/UBE2C downstream pathway inhibition of 94%. VPC-70063 can be used for studies about anticancer.
  • $47
In Stock
Size
QTY
CPI0610
T20911380087-89-7
CPI0610 (CPI-0610) is an effective, specific, and cell-active BET bromodomain inhibitor CPI-0610 inhibits BRD4-BD1 (IC50: nM).
    Inquiry
    Mycro 3
    T4367944547-46-0
    Mycro 3 is potent and selective for c-Myc in whole cell assays.
    • $45
    In Stock
    Size
    QTY
    RK-9123016
    T28543955900-27-3In house
    RK-9123016 is a SIRT2 inhibitor. RK-9123016 increases the acetylation level of eukaryotic translation initiation factor 5A (eIF5A), a physiological substrate of SIRT2, and reduces cell viability of human breast cancer cells accompanied with a decrease in c-Myc expression.
    • $40
    In Stock
    Size
    QTY
    Nicotinamide N-oxide
    T06171986-81-8
    Nicotinamide N-oxide (Nicotinamide 1-oxide) is recognized as an in vivo metabolite of nicotinamide which is a precurser of nicotinamide-adenine dinucleotide (NAD+) in animals. The enzyme that catalyzes the reduction of nicotinamide N-oxide to nicotinamide in the liver is xanthine oxidase.
    • $33
    In Stock
    Size
    QTY
    KJ Pyr 9
    T15665581073-80-5
    KJ Pyr 9 is an MYC inhibitor (Kd: 6.5 nM in vitro assay).
    • $33
    In Stock
    Size
    QTY
    TargetMol | Inhibitor Sale
    10074-A4
    T9628312631-87-1
    10074-A4 is a c-Myc binding compound that associates with c-Myc[370–409] and acts as a ligand cloud around a protein cloud , exhibiting distinct characteristics compared to a non-binding ligand.
    • $57
    In Stock
    Size
    QTY
    TargetMol | Citations Cited